NCT05540223View on ClinicalTrials.gov

Safety and Clinical Performance of the DREAMS 3G Resorbable Magnesium Scaffold System

NANot yet recruitingINTERVENTIONAL
Enrollment

1,859

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 29, 2032

Conditions
Coronary Artery DiseaseAtherosclerosis, CoronaryMyocardial IschemiaIschemic Heart DiseaseAcute Coronary SyndromeAngina Pectoris
Interventions
DEVICE

DREAMS 3G RMS

Subject undergoes implantation of DREAMS 3G RMS

DEVICE

Xience DES

Subject undergoes implantation of Xience DES

Sponsors

Lead Sponsor

Biotronik AG
All Listed Sponsors
lead

Biotronik AG

INDUSTRY

NCT05540223 - Safety and Clinical Performance of the DREAMS 3G Resorbable Magnesium Scaffold System | Biotech Hunter | Biotech Hunter